Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long acting atypical antipsychotic
Authors Pierre Chue
Published 15 March 2007 Volume 2007:3(1) Pages 13—39
Department of Psychiatry University of Alberta, Edmonton, Alberta, Canada
Objective: To review the pharmacokinetics, efficacy, safety, and cost-effectiveness of longacting risperidone.
Methods: Studies published between January 2000 and October 2006 evaluating the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone were reviewed, as identified from literature searches using Medline and EMBASE. Abstracts and posters on long-acting risperidone presented at key psychiatry congresses and available in the public domain during this time period were also reviewed.
Results: The unique pharmacokinetic profile of long-acting risperidone is derived from the encapsulation of risperidone in a glycolide/lactide matrix in the form of microspheres such that after a single intramuscular injection, significant plasma levels of the drug are achieved after week 3. Steady state, after repeated administration at 2-week intervals, is achieved after 3 injection cycles. Short- and long-term studies have demonstrated that long-acting risperidone (25, 37.5, or 50 mg) is both efficacious and well tolerated in a wide variety of patients with schizophrenia and related psychoses. Most patients can be switched from other oral and longacting antipsychotic agents without compromising efficacy and safety. Long-acting risperidone may also reduce overall healthcare costs by decreasing rates of relapse and hospitalization.
Conclusion: The assured delivery of an atypical antipsychotic medication with long-acting risperidone has important implications for patient compliance, maintenance of stability, consistency of treatment, and improving patient outcomes including the achievement of remission.
Keywords: long-acting injectable risperidone, efficacy, safety, pharmacokinetics, pharmacoeconomics, schizophrenia